2Thomas MF Jr. Overview of resistance in 1990s[J]. Chest, 1999, 115: 3s-8s. 被引量：1
3Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of an timicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1996-1997 respiratory season[J]. Diagn Microb Infect Dis, 1997, 29: 249-257. 被引量：1
4CDC. Update. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997[J]. MMWR, 1997, 46: 813-815. 被引量：1
5Murray BE. Vancomycin-resistant enterococci[J]. Am J Med, 1997, 102: 284-293. 被引量：1
6Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program[J]. Clin Infect Dis, 1996, 23: 779-784. 被引量：1
7Watanabe M, Lyobe S, Inoue M, et al. Transferableimipe-men resistance in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1991, 35: 147-151. 被引量：1
8Suh B, Shapiro T, Jones R, et al. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species[J]. Diagn Microbiol Infect Dis, 1995, 21: 111-114. 被引量：1
9Lecso-Bornet M, Bergogne-Berezi N. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three β-lactams and five β-lactam β-lactamase inhibitor combinations[J]. J Antimicrob Chemother, 1997, 40: 717-720. 被引量：1
